Comparative Pharmacology
Head-to-head clinical analysis: KYLEENA versus NEXTSTELLIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KYLEENA versus NEXTSTELLIS.
KYLEENA vs NEXTSTELLIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that suppresses endometrial proliferation, thickens cervical mucus, and induces endometrial atrophy. It also partially inhibits ovulation.
Combination oral contraceptive: estrogen (estetrol) and progestin (drospirenone) suppress gonadotropin release, inhibiting ovulation; increase cervical mucus viscosity, impeding sperm penetration; alter endometrial lining, reducing implantation likelihood.
KYLEENA (levonorgestrel-releasing intrauterine system 19.5 mg) is inserted into the uterine cavity by a healthcare professional. One system releases levonorgestrel at approximately 17.5 mcg/day initially, decreasing to 7.4 mcg/day after 1 year and 5.1 mcg/day after 3 years, and is effective for up to 5 years.
One tablet orally once daily, each tablet containing drospirenone 3 mg and estetrol 14.2 mg, taken continuously without a break.
None Documented
None Documented
Terminal elimination half-life is approximately 25 hours (range 18–30 hours) after repeated dosing; supports once-daily dosing but not applicable for IUD as systemic absorption is minimal.
Drospirenone: 30 hours; ethinyl estradiol: 12 hours. The long half-life allows once-daily dosing and stable serum concentrations.
Renal (fecal negligible). Levonorgestrel is extensively metabolized; metabolites are excreted primarily in urine (40–68%) and to a lesser extent in feces (16–48%).
Urine (60%) and feces (35%); drospirenone and metabolites, with enterohepatic recirculation.
Category C
Category C
Contraceptive
Contraceptive